Engflag

Pimavanserin

Quick links to important sections

Pimavanserin

Pimavanserin_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pimavanserin

Property Description
Active ingredient Pimavanserin (as tartrate salt)
Form Oral tablet, Oral capsule
Pharmacological class Atypical Antipsychotic, Selective Serotonin Inverse Agonist (SSIA)
Common use Relieving psychosis symptoms (e.g., hallucinations, delusions)
Origin Synthetic organic compound

What Type of Medicine is Pimavanserin?

Pimavanserin is classified as an atypical antipsychotic and is a unique Selective Serotonin Inverse Agonist (SSIA). The medicine’s core substance is Pimavanserin, administered as the salt, Pimavanserin tartrate, a synthetic organic compound. This is a prescription-only, single-ingredient product designed for specific neurological modulation. Clinical research has established Pimavanserin as one of the few medications supported by pharmacological studies specifically developed to address symptoms related to psychosis through a non-dopaminergic pathway, confirming its differentiated status.

Pimavanserin’s Unique Non-Dopaminergic Profile

The unique mechanism of Pimavanserin is defined by its non-dopaminergic profile; it works primarily by engaging the serotonin 5-HT2A receptor as an inverse agonist, actively suppressing the receptor’s excessive signaling. This approach sharply contrasts with most older or traditional antipsychotics that rely on blocking the dopamine D2 receptor. This specific targeting of the serotonergic system provides a focused tool that is clinically recognized for its potential to help alleviate symptoms such as hallucinations and delusions while aiming to avoid the motor side effects often linked to widespread dopamine blocking.

Pimavanserin: Forms and Formulation

Pimavanserin is intended for systemic action and is readily available for oral intake as both an oral tablet and an oral capsule. The formulation contains the Pimavanserin tartrate active ingredient along with the necessary pharmaceutical excipients to create a stable, single-ingredient preparation. This availability in different oral forms offers a specific level of flexibility for patient convenience when taking the prescribed medicine.

What side effects are possible with Pimavanserin?

Possible side effects and safety information

The official regulatory safety profile of Pimavanserin is structured around specific risks and documented adverse reactions, as established by government health authorities.

Serious Safety Information and Warnings

Official labeling includes a Boxed Warning concerning the use of antipsychotic drugs, including this class, in elderly patients with dementia-related psychosis, citing an increased risk of death. The medication is not approved for this condition unless the psychosis is specifically related to Parkinson's disease.

A major safety consideration is the potential for QT interval prolongation, a change in the electrical activity of the heart. This risk may increase the potential for serious, life-threatening heart rhythm abnormalities, such as Torsade de Pointes. Due to this risk, the medicine is contraindicated in individuals with a history of QT prolongation or pre-existing cardiac arrhythmias.

Common Adverse Reactions and System Groupings

Adverse reactions classified as Common (occurring in geq5% of patients and at least twice the rate of placebo in trials) include peripheral edema (swelling), nausea, and confusional state. Other reactions reported at an incidence greater than placebo involve several system-organ classes, such as the Gastrointestinal system (constipation), Psychiatric system (hallucination), and Nervous system (gait disturbance).

Population-Specific Constraints

The medicine is not recommended for use in patients who have severe renal impairment (creatinine clearance <30 mL/min), as safety data for this population are not fully established in regulatory documents. Additionally, the label details mandatory adjustments to the regimen when the medicine is used with strong or moderate inhibitors or inducers of the CYP3A4 enzyme due to potential changes in drug exposure.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Pimavanserin

Overdose scope

Property Official Regulatory Statement (FDA/EMA Alignment)
Documented overdose presentations Nausea and Vomiting (observed as dose-limiting effects in pre-marketing trials).
Physiological systems affected (as stated in label) Cardiovascular System (potential for QT Interval Prolongation and Arrhythmias).
Dose-related or exposure-related factors (if applicable) The long plasma half-life (approximately 57 hours) must be considered during management.
Population-specific overdose notes (if applicable) The official prescribing information does not contain specific, differentiated management instructions for any particular population group.
Emergency-response statements (as written in official documents) Management requires symptomatic and supportive treatment; No specific antidote is known; Continuous ECG monitoring is mandated.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for any suspected overdose; Contact a Certified Poison Control Center for specialized guidance.

Overdose classifications (high-level)

Property Official Regulatory Statement (FDA/EMA Alignment)
Severity classification (as defined in official documents) The primary concern is the potential for serious cardiac events (e.g., Torsade de Pointes), requiring strict monitoring.
Regulatory basis (EMA / FDA / etc.) Information derived from the U.S. Food and Drug Administration (FDA) Prescribing Information.
Overdose-context constraints (as defined in official documents) Monitoring must account for the possibility of multiple drug involvement, particularly other QT-prolonging agents.

Resulting overdose structure

Official overdose statements:

  • Overdose may be characterized by the manifestation of nausea and vomiting.
  • The core risk is the potential for QT interval prolongation and subsequent severe cardiac arrhythmias.
  • Immediate medical attention must be sought, and a Poison Control Center should be contacted upon suspicion of overdose.
  • No specific antidote is known for Pimavanserin.
  • Management must consist of symptomatic and supportive treatment, with mandatory continuous ECG monitoring to assess cardiac status.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Pimavanserin overdose profile by the absence of a specific antidote and the critical risk of QT interval prolongation. This potential for severe cardiac events mandates that patients seek immediate medical attention for any suspected overdose. The required emergency protocol focuses entirely on symptomatic and supportive treatment alongside mandatory continuous cardiac monitoring.

Therapeutic Uses of Pimavanserin

What Pimavanserin Treats: Main Uses and Benefits

Pimavanserin is commonly used to help with reducing the frequency and severity of hallucinations and delusions—the characteristic psychotic symptoms—that occur in patients with Parkinson's disease psychosis (PDP). This medication is used to manage psychotic symptoms that arise during the course of established Parkinson's disease. The primary use is applied in addressing conditions characterized by periods of heightened symptoms related to increased neurological activity, which is considered relevant for easing symptoms that create noticeable physiological strain, specifically hallucinations and delusions.

The medication is relevant for easing symptoms and is used for managing these symptoms without aggravating the underlying motor features of Parkinson's disease. This approach is relevant when supportive symptom management is appropriate, as it helps patients maintain existing motor function while contributing to easing the burden of psychosis.

“The therapeutic benefit supports easing distressing symptoms and helps patients cope more steadily with symptom fluctuations.”

By alleviating the confusion and distress caused by severe symptoms, the treatment provides support that contributes to a practical benefit: improved day-to-day comfort. This helps maintain a sense of stability when symptoms are more noticeable, and may assist with easing the demands and stress placed on caregivers.

Quick Fact: Relief for Psychotic Symptoms in Parkinson's Disease

Regulatory References

  1. Pimavanserin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Exclusion Criteria

Pimavanserin's eligibility is strictly defined by regulatory documents, focusing on patient age, cardiac risk, and organ function status.

Eligibility Classification Population Restriction (Official Wording)
Contraindicated Patients with a known hypersensitivity reaction to pimavanserin or any of its components.
Contraindicated Patients with known QT prolongation or those using other drugs that prolong the QT interval.
Use Not Approved Elderly patients with dementia-related psychosis unrelated to Parkinson’s disease psychosis, due to the regulatory Boxed Warning regarding increased mortality risk.
Age Restriction Safety and efficacy have not been established in pediatric patients (under 18 years of age).
Use Not Recommended Patients with severe renal impairment (CrCL < 30 mL/min) or any degree of hepatic impairment.

The official documents restrict use to the adult population and mandate avoidance in patients with cardiac risk factors, such as a history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia, or hypomagnesemia. Regarding reproductive status, no human data are available to assess risk during pregnancy or lactation, which limits use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pimavanserin's potential for drug interactions is tied to its metabolism and its effect on the heart’s electrical activity. The product is metabolized primarily by the Cytochrome P450 (CYP) 3A4 enzyme. Medicines that strongly inhibit or induce this enzyme can significantly affect pimavanserin levels in the body.

Pharmacokinetic Interactions (Metabolism-based)

Interacting Drug Category Resulting Effect on Pimavanserin Regulatory Constraint
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) Increases pimavanserin exposure. Requires a dose reduction of pimavanserin.
Strong or Moderate CYP3A4 Inducers (e.g., rifampin, St. John’s wort) Decreases pimavanserin exposure, risking reduced efficacy. Avoid concomitant use of the two medicines.

Pharmacodynamic Interactions (Cardiac Risk)

Pimavanserin is known to cause a concentration-dependent prolongation of the QT interval, a measure of heart rhythm. Therefore, its use should be avoided in combination with other medicines known to prolong the QT interval. This includes specific antiarrhythmic drugs (Class 1A and Class 3, such as quinidine or amiodarone) and certain antipsychotics and antibiotics. Concomitant use with these substances may increase the risk of serious cardiac arrhythmia, including Torsade de Pointes.

Mechanism of Action

Pimavanserin functions as a selective serotonin 5-HT2A receptor inverse agonist and functional antagonist. Its primary biological target is the G-protein coupled 5-HT2A receptor, where it exhibits high binding affinity. Pimavanserin also demonstrates significantly lower affinity for the 5-HT2C receptor, acting as an inverse agonist and antagonist at this site as well. The drug lacks appreciable affinity for dopaminergic, histaminergic, muscarinic, and adrenergic receptors. Its interaction profile is distinct, specifically avoiding the D2 dopamine receptor.

As an inverse agonist at the 5-HT2A receptor, pimavanserin binds and stabilizes the receptor in an inactive conformation. This action reduces the intrinsic constitutive activity of the receptor, thereby inhibiting the downstream intracellular signaling cascade. The 5-HT2A receptor is coupled to the Gq protein, which typically leads to the activation of phospholipase C (PLC) and the subsequent release of Ca^2+ from internal stores. By blocking this Gq-coupled pathway, pimavanserin modifies serotonergic neurotransmission, resulting in a system-level modulation of neurotransmitter signaling within the central nervous system.

Dosage and Administration Information

How to Use Pimavanserin

Administration Scope

Pimavanserin is administered orally and is available in a 34 mg capsule and 10 mg or 17 mg tablets. The standard recommended dose is 34 mg once daily. Initial dose titration is not required when starting the medication. It may be taken with or without food.

Preparation Requirements

If swallowing the capsule is difficult, the contents can be opened and sprinkled onto a tablespoon of soft food like applesauce or pudding, and must be consumed immediately without chewing.

Frequency and Adjustments

The medicine is used as a once-daily regimen intended for continuous, long-term administration. For patients with severe renal impairment (CrCL < 30 mL/min), use is not recommended. When strong CYP3A4 inhibitors are co-administered, the dose must be reduced to 10 mg once daily to manage drug exposure. Use with strong or moderate CYP3A4 inducers should be avoided.

Missed Dose Rules

If a dose is missed, it should be skipped, and the patient should resume the regimen at the next scheduled time; two doses should never be taken at once to compensate for the missed dose.

Connection to the Overall Use Protocol

The official instructions define a standardized, once-daily oral protocol using a fixed dose, which establishes clear procedural boundaries for correct long-term administration. The protocol is flexible regarding food intake but includes mandatory dose modifications and restrictions based on specific pharmacokinetic factors and renal status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pimavanserin

Evidence for use in Psychosis in Parkinson's Disease

Pimavanserin was studied for its use in patients with Parkinson's disease who experience hallucinations and delusions. The core data informing this area was derived from short-term, controlled trials (RCTs) and subsequent open-label extension studies that explored outcomes related to psychotic symptoms. In these studies, some groups of patients received the active medicine while others received a placebo, allowing researchers to observe how symptoms evolved in the observed populations.

Studies specifically research examined motor function to monitor the physical symptoms of Parkinson's disease; these studies reported data show patterns related to minimal change in motor scores. The primary evidence base for the initial regulatory clearance was based predominantly on the results of a single short-term RCT that met its primary endpoint. While long-term outcomes are not fully established in controlled trials, observational settings using real-world evidence have been conducted to observe patterns associated with metrics of daily functioning or system utilization in this patient group.

Evaluation of the Medicine in Dementia-Related Psychosis

Pimavanserin was evaluated in a Phase III trial exploring its use for psychosis in a wider group of patients diagnosed with various forms of dementia, which are conditions characterized by fluctuating or episodic manifestations. The specific trial design was a randomized discontinuation trial, meaning that patients who met pre-defined criteria for symptom stability were then randomly assigned to either continue the medicine or switch to a placebo.

Subgroup analysis data show patterns related to the Parkinson's disease dementia group, which researchers noted was associated with most of the observations reported from the study. Research exploring other complex dementias did not result in regulatory clearance for that use; therefore, for those conditions, certainty remains low and the available data are still emerging.

Research Gaps and Areas of Uncertainty

Follow-up durations were limited to six weeks in the initial pivotal RCTs. While open-label extension studies contribute to understanding symptom patterns over extended periods, these studies are non-controlled. Long-term effects are not fully established in the same rigorous manner as the initial short-term comparisons. Furthermore, the primary evidence base relies heavily on a single short-term RCT that met its primary endpoint for the approved indication, which means comparative evidence is lacking against other types of therapies in head-to-head RCTs.

Frequently Asked Questions (FAQ)

Common questions about Pimavanserin (FAQ)

Q: How long does it typically take to start feeling the effects of Pimavanserin?

Clinical trials supporting the drug’s approval were short-term, lasting six weeks, and demonstrated a reduction in symptoms during this period. Because the primary evidence is based on these short-term studies, individual response timing beyond this period is not fully established.

Q: Is weight gain a common side effect when taking Pimavanserin?

According to the official product information, weight gain is not listed among the most common adverse reactions. These reactions are defined as those occurring in five percent or more of patients and at least twice the rate of placebo in clinical trials. Only adverse reactions meeting this specific threshold are generally categorized as common.

Q: What happens if I miss a dose of Pimavanserin?

Regulatory documents state that if a dose is missed, it should be skipped. Patients are advised to resume the regimen at the next scheduled time. Two doses should never be taken at once to compensate for a missed dose, as this could affect medicine exposure.

Q: Can Pimavanserin interact with common blood pressure medications?

Pimavanserin is known to affect the heart’s electrical activity, and official warnings advise avoiding its use with drugs that prolong the QT interval (a measure of heart rhythm). This caution may include certain antiarrhythmic or other medications. Information about all medications, including those for heart and blood pressure, should be shared with a healthcare provider before starting treatment.

Q: Does Pimavanserin affect blood sugar levels?

Pimavanserin belongs to the class of atypical antipsychotic medicines. This class has been associated with metabolic changes, including the potential for high blood sugar, or hyperglycemia. Official product information suggests that individuals with pre-existing diabetes may require monitoring.

Q: Can I take Pimavanserin if I have a liver condition?

Official regulatory documents indicate that Pimavanserin is not recommended for patients with any degree of hepatic impairment, which refers to a liver condition. This is because safety and efficacy data for this specific population are not fully established.

Q: What does the research say about Pimavanserin use in people with dementia?

The medicine is not approved for psychosis related to dementia, unless the psychosis is due to Parkinson’s disease. The official Boxed Warning for this drug class, including Pimavanserin, cites an increased risk of death in elderly patients with dementia-related psychosis.

Q: Is it common to feel nauseous when starting this medicine?

Nausea is classified as a common adverse reaction in the official product information, meaning it was reported by a significant percentage of patients in clinical trials. The exact timing of when this side effect may start (e.g., in the first few days) is not specified in the common adverse reactions data.

Q: What is the role of serotonin receptors in how Pimavanserin works?

Pimavanserin’s action is thought to be primarily through the serotonin 5-HT2A receptor, where it acts as an inverse agonist and antagonist. This highly selective mechanism acts on the serotonergic system, which contrasts with the action of many older antipsychotic medications.

Q: Is Pimavanserin a cure for Parkinson's disease psychosis or just a treatment for symptoms?

According to the official product labeling, Pimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is indicated for the treatment of these symptoms and not as a cure for the underlying disease.

Q: Are there generic versions of Pimavanserin available?

Pimavanserin is currently supplied as a brand-name product. According to regulatory status, a generic version is not yet commercially available for patients.

Q: What is the half-life of Pimavanserin?

The elimination half-life of Pimavanserin is approximately 57 hours. This is the time it takes for half of the medicine to be eliminated from the body. Its active metabolite (a substance created when the drug breaks down) has an even longer half-life of about 200 hours.

Q: Does Pimavanserin help with delusions as well as hallucinations?

Yes, regulatory documents indicate that the medicine is approved for the treatment of both hallucinations and delusions associated with Parkinson’s disease psychosis.

Q: Are there any restrictions on alcohol consumption while taking Pimavanserin?

It is unknown if drinking alcohol directly affects the drug's effectiveness. However, official drug information suggests that the risk of central nervous system side effects like confusion may be increased when alcohol is consumed while taking this medicine.

Q: Can Pimavanserin affect my ability to drive or operate machinery?

The official warning section notes that common adverse reactions include a confusional state and dizziness. Due to these potential effects, caution is advised when performing activities that require mental alertness, such as driving or operating complex machinery.

Q: Is Pimavanserin approved for use in younger adults?

Regulatory documents state that Pimavanserin is only approved for use in the adult population. The safety and effectiveness of the medicine have not been established in pediatric patients, defined as those under 18 years of age.

Q: Are there any specific tests needed before starting Pimavanserin?

Due to the risk of QT prolongation, assessment for pre-existing cardiac conditions or low levels of potassium or magnesium may be required, as these can affect heart rhythm. This assessment helps ensure appropriate use of the medicine.

Q: What is the maximum effective dose of Pimavanserin?

The standard recommended dose used in clinical trials and cited in official dosing guidelines is 34 mg, taken once daily. This is the dose that demonstrated efficacy in the main studies.

Q: How is Pimavanserin usually supplied (e.g., tablets, capsules)?

The medicine is available for oral administration in different strengths and forms. It is supplied as capsules (34 mg) and also as tablets (10 mg and 17 mg).

Q: Why do doctors prescribe Pimavanserin for psychosis but not for depression?

Pimavanserin is specifically approved for treating the hallucinations and delusions associated with Parkinson's disease psychosis. Its unique mechanism of action, which primarily targets the 5-HT2A receptor, aligns with this specific indication rather than the broader treatment of depression.

Q: Is it normal to feel a little dizzy when first starting Pimavanserin?

Dizziness is a reported adverse reaction noted in the clinical trials, but it was not one of the most common side effects. While it may occur, its frequency in clinical data is lower than the most common reported side effects.

How should Pimavanserin be stored and disposed of?

Storage and Protection Requirements

Pimavanserin must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with brief excursions permitted up to 30 C. To maintain product stability, the medication must be kept in the original container and the container must remain tightly closed. It is mandatory to keep Pimavanserin out of the sight and reach of children and to protect the product from excess heat, light, and moisture.

Official Disposal Instructions

Unused or expired Pimavanserin must be disposed of according to local regulations and official guidelines. Regulatory instructions state that the medicine should not be flushed down a toilet or sink. Community drug take-back programs are often the recommended method for discarding the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pimavanserin found in:

A-Z Index: